Other languages Myriad Genetics, Inc.

Equities

MYGN

US62855J1043

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
18.18 ^USD	+1.11%		-1.73%	-5.02%

Mar. 20	Myriad Genetics Gets US Patent for SneakPeek Snap Device	MT
Feb. 27	Transcript : Myriad Genetics, Inc., Q4 2023 Earnings Call, Feb 27, 2024

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Myriad Genetics, Inc. Provides Revenue Guidance for the First Quarter 2024	Feb. 27
Myriad Genetics, Inc. Updates Revenue Guidance for the Fiscal Year 2024	Feb. 27
Myriad Genetics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 27
Myriad Genetics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 27
Myriad Genetics Acquires Intermountain Precision Genomics' Assets from Intermountain Health	Feb. 01
Myriad Genetics, Inc. completed the acquisition of select assets of laboratory business of Intermountain Precision Genomics.	Jan. 31
Myriad Genetics, Inc. Appoints George Daneker as President and Chief Clinical Officer of Oncology, Effective March 18, 2024	Jan. 30
Myriad Genetics Agrees to Acquire Select Assets of Intermountain Precision Genomics' Laboratory Business	Jan. 19
Myriad Genetics Names Scott Leffler as Chief Financial Officer, Reiterates Outlook	Dec. 21
Myriad Genetics, Personalis Collaborate to Market ImmunoID NeXT Platform	Nov. 16
Myriad Genetics, Inc. and Personalis, Inc. Partner to Market Solutions to Pharma Customers	Nov. 16
Myriad Genetics Shares Climb as Q3 Loss Narrower Than Estimated, FY Revenue Guidance Raised	Nov. 07
Myriad Genetics, Inc. Provides Financial Guidance for 2023 and 2024	Nov. 06
Myriad Genetics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 06
Myriad Genetics Insider Sold Shares Worth $470,622, According to a Recent SEC Filing	Nov. 03
Myriad Genetics Names Sam Raha as Chief Operating Officer	Nov. 01
Myriad Genetics, Inc. Appoints Samraat S. Raha as Chief Operating Officer, Effective as of December 11, 2023	Nov. 01
Qiagen, Myriad Genetics Sign Collaboration Deal for Cancer Diagnostic Tests	23-10-26
Myriad Genetics, Qiagen to Develop Companion Diagnostic Tests for Cancer	23-10-26
QIAGEN and Myriad Genetics Partner to Advance Companion Diagnostics Development for Cancer	23-10-26

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Myriad Genetics, Inc.

Equities

MYGN

US62855J1043

Other languages

Filters